Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel
NASDAQ:GNLX

Genelux Q3 2026 Earnings Date & Estimates

Genelux logo
$1.94 -0.13 (-6.28%)
As of 02:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Genelux is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Genelux in Q3 2026

Genelux is expected to post earnings of -$0.20 per share. In the same quarter a year earlier Genelux reported -$0.21 per share. Genelux last reported on August 13, 2026, posting -$0.21 per share and missing the -$0.1967 consensus estimate. Genelux has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.20
Prior-Year EPS
-$0.21

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.21 (Missed by -$0.0133)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Genelux Q3 2026 Earnings FAQ

Genelux (NASDAQ:GNLX) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Genelux's Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Genelux to post earnings of -$0.20 per share for Q3 2026.

Genelux Earnings Headlines

Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ...
September 9, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genelux-announces-publication-of-a-deep-and-durable-response-in-a-platinum-relapsed-small-cell-lung-cancer-patient-following-systemically-delivered-olvi-vec-primed-immunochemotherapy-1036533892
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3359047/0/en/genelux-announces-publication-of-a-deep-and-durable-response-in-a-platinum-relapsed-small-cell-lung-cancer-patient-following-systemically-delivered-olvi-vec-primed-immunochemothera.html
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
November 10 at 1:00 AM  |  Behind the Markets (Ad)
Genelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung Cancer
August 13, 2026  |  quiverquant.comQ
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344971/0/en/genelux-corporation-reports-second-quarter-financial-results-and-provides-business-updates.html
Genelux (GNLX) Stock Forecast & Price Target
July 11, 2026  |  investing.comhttps://www.investing.com/equities/genelux-consensus-estimates
See More Genelux Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genelux? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genelux and other key companies, straight to your email.

About Genelux

Genelux (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company’s lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, genetically modified oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating an immune response against cancer.

Genelux is evaluating Olvi-Vec in combination with other treatments across multiple solid-tumor indications. Its clinical development efforts have included ovarian cancer, where the candidate is being studied in patients with advanced or recurrent disease, as well as other potential applications in cancers such as colorectal and lung cancer.

Founded in 2001 and headquartered in San Diego, California, Genelux conducts its research and clinical development activities primarily in the United States. The company was founded by Thomas Z. He, Ph.D., who has served as its president and chief executive officer.

View Genelux Profile
Earnings Tools